London-based AI Startup ScienceMachine Secures $3.5M In Pre-Seed Round

The startup has built an AI agent called Sam — a fully autonomous bioinformatician that works 24/7. Sam automates the entire data analysis process, helping researchers discover faster and reduce costs.

ScienceMachine tackles a major problem in biotech: research teams are overwhelmed by complex data but don’t have enough skilled data scientists. At the same time, scientists lack the tools or time to analyze this data on their own.

Sam fills this gap. It connects directly to lab systems, processes data in real-time, and finds insights and patterns — all without human help. What usually takes a whole team, Sam does alone, speeding up discoveries in the life sciences.

Lorenzo Sani, CEO and Co-founder of Science Machine, shared: Our goal is to help biopharma make groundbreaking discoveries faster and cheaper. Our AI agent works around the clock, analysing research data from lab to clinic, turning raw data into breakthroughs in hours, instead of months. And we are only at the beginning. We feel like AI will truly transform research and discovery in the coming years.

Sam takes care of the entire process — from cleaning data to running analysis and creating visualizations — all on its own, around the clock. This speeds up research and cuts discovery costs significantly.

Read Also - Paris-based Startup Tandem Raises $3.8M In Seed Round

Early users say they’re getting results three times faster, for much less money, and with better quality than before.

Just a month after launching, ScienceMachine has already signed multiple contracts and is seeing strong inbound demand.

The $3.5M funding round was led by Revent and Nucleus Capital, along with several strategic angel investors.

Rebecca Brill, Principal, Revent, said: ScienceMachine is one of the most impressive examples we’ve seen of pure execution. With just two people, they’ve built a product that’s not only best-in-class technically, but already delivering measurable value to customers. They’re perfectly positioned to disrupt one of the largest and most important markets in the world.

Maximilian Schwarz, General Partner at Nucleus, shared his belief that agent-based architectures will soon become the primary way scientists interact with software.

ScienceMachine is ideally positioned to dramatically expand access to complex bioinformatics for wet-lab scientists and speed up iteration cycles, ultimately increasing the addressable market and accelerating R&D timelines.

The funding will be used to grow the team—especially in sales and pharma partnerships—and to further develop the product.

ScienceMachine also aims to move beyond biotech startups and work with larger companies, where contracts are bigger and demand for scalable data automation is even stronger.

About ScienceMachine

Sam is an AI Data Scientist built for biotech. It organizes, analyzes, and extracts insights from research data, significantly boosting R&D efficiency and accelerating scientific discovery.